Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.25100/cm.v51i2.4279 http://scihub22266oqcxt.onion/10.25100/cm.v51i2.4279 33012890!7518729!33012890     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=33012890&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Colomb+Med+(Cali) 2020 ; 51 (2): e4279 Nephropedia Template TP {{tp|p=33012890|t=2020. Drug Repositioning for COVID-19 |pdf=|usr=}}{{33012890}} gab.com Text Drug Repositioning for COVID-19 JO: Colomb Med (Cali) http://www.kidney.de/pget.php?&tw=1&pmid=33012890 #FOAvip Drug repositioning is a strategy that identifies new uses of approved drugs to treat conditions different from their original purpose. With the advance of COVID-19 and the pandemic declaration; It has become the closest alternative to reduce the advance of the virus. Antimalarial, antiviral drugs, antibiotics, glucocorticoids, monoclonal antibodies, among others, are being studied; their findings, although preliminary, could establish a starting point in the search for a solution. In this review, we present a selection of drugs, of different classes and with potential activity against COVID-19, whose trials are ongoing; and as proofs of concept, double blind, add-on event-driven, would allow proposing research that generates results in less time and preserving quality criteria for drug development and approval by regulatory agencies. Twit Text FOAVip Drug Repositioning for COVID-19 ????Colomb Med (Cali) http://www.kidney.de/pget.php?&tw=1&pmid=33012890 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33012890 #FOAvip English Wikipedia <ref>{{Cite pmid|33012890}}</ref> Drug Repositioning for COVID-19 #MMPMID33012890 Benavides-Cordoba V Colomb Med (Cali) 2020[Jun]; 51 (2): e4279 PMID33012890show ga Drug repositioning is a strategy that identifies new uses of approved drugs to treat conditions different from their original purpose. With the advance of COVID-19 and the pandemic declaration; It has become the closest alternative to reduce the advance of the virus. Antimalarial, antiviral drugs, antibiotics, glucocorticoids, monoclonal antibodies, among others, are being studied; their findings, although preliminary, could establish a starting point in the search for a solution. In this review, we present a selection of drugs, of different classes and with potential activity against COVID-19, whose trials are ongoing; and as proofs of concept, double blind, add-on event-driven, would allow proposing research that generates results in less time and preserving quality criteria for drug development and approval by regulatory agencies. |*Drug Repositioning[MESH] |COVID-19[MESH] |COVID-19 Drug Treatment[MESH] |Coronavirus Infections/*drug therapy/epidemiology/virology[MESH] |Drug Approval[MESH] |Drug Development[MESH] |Humans[MESH] |Pandemics[MESH]Drug Repositioning for COVID-19 (epmc).pdf DeepDyve Pubget Overpricing